Just 61% of hospitals surveyed evaluated models for accuracy on their own data, and less than half evaluated the models for ...
Naveris, Inc., the leader in precision oncology diagnostics for viral-induced cancers, today announced the expanded commercial availability of the NavDx test for Molecular Residual Disease (MRD) ...